Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock
Treatment Efficacy
About this trial
This is an interventional treatment trial for Treatment Efficacy
Eligibility Criteria
Inclusion Criteria: adult patients aged > 18 years old diagnosis of septic shock (patient with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial blood pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol\L (>18 mg\dL) in the absence of hypovolemia). positive culture confirming linezolid susceptibility. Exclusion Criteria: Patient refusal. Known allergy to linezolid. Pregnancy and lactation. Severe hepatic failure (Child-Pugh C). Thrombocytopenia (platelet count < 80,000/mm3). Disseminated intravascular coagulation (DIC). Hematologic disease, and concurrent use of other medications that may interact with linezolid (i.e., macrolides, serotonin modulators), or drug-associated thrombocytopenia.
Sites / Locations
- Ain Shams UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
continuous infusion
intermittent infusion
seventy Patients in the continuous infusion group will receive an intravenous loading dose of 600 mg of Linezolid for 60 min, followed by a continuous infusion of 1200 mg/day (50 mg/h)
seventy patients in the intermittent infusion group will administrate 600 mg of linezolid IV every 12 h for 60 min